Search

Your search keyword '"Feldhamer, Ilan"' showing total 157 results
Start Over Author "Feldhamer, Ilan"
157 results on '"Feldhamer, Ilan"'

16. Treatment Persistence of Apremilast Among Patients with Psoriatic Arthritis

Author

Haddad,Amir, Stein,Nili, Lavi,Idit, Shynkar,Lisa, Bergman,Irina, Feldhamer,Ilan, Cohen,Arnon Dov, Saliba,Walid, Zisman,Devy, Haddad,Amir, Stein,Nili, Lavi,Idit, Shynkar,Lisa, Bergman,Irina, Feldhamer,Ilan, Cohen,Arnon Dov, Saliba,Walid, and Zisman,Devy

Abstract

Amir Haddad,1 Nili Stein,2 Idit Lavi,2 Lisa Shynkar,3 Irina Bergman,3,4 Ilan Feldhamer,5 Arnon Dov Cohen,5,6 Walid Saliba,2,4 Devy Zisman1,4 1Rheumatology Unit, Carmel Medical Center, Haifa, Israel; 2Department of Epidemiology, Clalit Health Services, Haifa, Israel; 3Internal Medicine Department, Carmel Medical Centre, Haifa, Israel; 4Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel; 5Chief Physician’s Office, Central Headquarters, Clalit Health Services, Tel Aviv, Israel; 6Siaal Research Center for Family Medicine and Primary Care, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheba, IsraelCorrespondence: Amir Haddad, Rheumatology Unit, Carmel Medical Centre, 7 Michal Street, Haifa, Israel, Tel +972-4-8250486, Email Haddadamir@yahoo.com; Amirha3@clalit.org.ilIntroduction: Persistence in drug therapy reflects treatment effectiveness and tolerability. We aim to estimate the persistence of apremilast prescribed to patients with psoriatic arthritis (PsA) and to identify characteristics associated with treatment discontinuation in a real-world setting.Methods: Patients with PsA treated with apremilast from January 2016 were identified from a large health database and followed until medication stop date (using 3-months grace period), death or the end of observation period (June 2021). Demographic data, Charlson comorbidity index and concomitant and previous use of conventional and biologic DMARDs were extracted. The reasons for drug discontinuation were manually retrieved from patient charts. Time to discontinuation was estimated using survival analysis using Kaplan–Meier functions.Results: Overall, 568 PsA patients treated with apremilast were identified. The mean age was 55.3± 14.0 years, of whom 332 (58.5%) were females, 38.4% were obese (BMI> 30), 75.2% had a Charlson comorbidity index> 1, 24.1% were on concomitant treatment with methotrexate and 72

Published
2023

26. Dose‐dependent association of proton pump inhibitors use with gastric intestinal metaplasia among Helicobacter pylori‐positive patients

Author

Snir, Yifat, primary, Leibovitzh, Haim, additional, Leibovici‐Weissman, Yaara, additional, Vilkin, Alex, additional, Cohen, Arnon D., additional, Shochat, Tzippy, additional, Niv, Yaron, additional, Dotan, Iris, additional, Feldhamer, Ilan, additional, Boltin, Doron, additional, and Levi, Zohar, additional

Published
2021
Full Text
View/download PDF

27. sj-pdf-1-ueg-10.1177_2050640620951403 - Supplemental material for Dose-dependent association of proton pump inhibitors use with gastric intestinal metaplasia among Helicobacter pylori-positive patients

Author

Snir, Yifat, Leibovitzh, Haim, Leibovici-Weissman, Yaara, Vilkin, Alex, Cohen, Arnon D, Tzippy Shochat, Niv, Yaron, Dotan, Iris, Feldhamer, Ilan, Boltin, Doron, and Levi, Zohar

Subjects
FOS: Clinical medicine, FOS: Biological sciences, 111199 Nutrition and Dietetics not elsewhere classified, FOS: Health sciences, 110308 Geriatrics and Gerontology, 69999 Biological Sciences not elsewhere classified, 111299 Oncology and Carcinogenesis not elsewhere classified
Abstract

Supplemental material, sj-pdf-1-ueg-10.1177_2050640620951403 for Dose-dependent association of proton pump inhibitors use with gastric intestinal metaplasia among Helicobacter pylori-positive patients by Yifat Snir, Haim Leibovitzh, Yaara Leibovici-Weissman, Alex Vilkin, Arnon D Cohen, Tzippy Shochat, Yaron Niv, Iris Dotan, Ilan Feldhamer, Doron Boltin and Zohar Levi in United European Gastroenterology Journal

Published
2020
Full Text
View/download PDF

43. Impact of flash glucose monitoring on glucose control and hospitalization in type 1 diabetes: A nationwide cohort study.

Author

Tsur, Anat, Cahn, Avivit, Israel, Meirav, Feldhamer, Ilan, Hammerman, Ariel, and Pollack, Rena

Subjects
TYPE 1 diabetes, HEALTH maintenance organizations, GLYCEMIC control, HOSPITAL care, GLUCOSE
Abstract

Background: We evaluated the impact of flash continuous glucose monitoring (FCGM) on glycemic control and healthcare burden in a large real‐world cohort of patients with type 1 diabetes (T1D) initiating FCGM technology. Methods: In this retrospective cohort study, we included adults (age ≥18 years) with T1D from a large Health Maintenance Organization in Israel, who initiated FCGM during 2018. Primary outcomes included change in HbA1c ≥3 months following FCGM commencement and change in rate of internal‐medicine hospitalization. Additional outcomes included changes in glucose test strip purchases, diabetes related outpatient health care visits and hospitalization for diabetic ketoacidosis (DKA) and/or severe hypoglycemia. Results: The study included 3490 patients, followed for a median of 14 (inter‐quartile range 11‐15) months after FCGM commencement. Among 2682 patients with an HbA1c measured both at baseline and ≥3 months after FCGM initiation, average HbA1c declined from 8.1% ± 1.46% to 7.9% ± 1.31% (P <.001) at first measurement and was maintained during follow up. Specifically, in those with HbA1c ≥8%, a mean decline of 0.5% (P <.001) was observed. A clinically significant HbA1c reduction of ≥0.5% was experienced by 25.5% of the patients. The rate of internal medicine hospitalization, visits to primary care, or visits to endocrine/diabetes specialists in the period following FCGM commencement vs the 6 months prior was significantly reduced (P <.001). Hospitalization for DKA and/or hypoglycemia declined as well (P =.004). Conclusions: FCGM was associated with significant and durable improvement in glycemic control as well as reduced consumption of healthcare services. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

44. Risk of serious infections, cutaneous bacterial infections, and granulomatous infections in patients with psoriasis treated with anti-tumor necrosis factor agents versus classic therapies: Prospective meta-analysis of Psonet registries

Author

Cazzaniga, Simone, Naldi, Luigi, Carretero, Gregorio, Cohen, Arnon D, Garcia-Doval, Ignacio, Ferrándiz, Carlos, Stern, Robert S, Feldhamer, Ilan, and Addis, Antonio

Subjects
610 Medicine & health
Abstract

BACKGROUND Anti-tumor necrosis factor (TNF) therapy in psoriasis has been associated with an increased risk of serious infections compared with nonbiologic systemic therapies. OBJECTIVE We sought to quantify the risk of: (1) serious infections (leading to hospitalization, sequelae, or death); and (2) "any infection," bacterial cutaneous infections, and granulomatous infections among patients receiving anti-TNF therapy compared with nonbiologics (acitretin, methotrexate, cyclosporine). METHODS We used prospective meta-analysis to combine data from the Psocare registry (Italy), Biobadaderm registry (Spain), and Clalit Health Services database (Israel), including 17,739 patients and 23,357.5 person-years of follow-up. RESULTS For serious infections, age, gender, and Charlson morbidity index adjusted hazard ratio of exposure to anti-TNFs compared with nonbiologics was 0.98 (95% confidence interval 0.80-1.19), for bacterial cutaneous infections it was 1.00 (95% confidence interval 0.62-1.61), and for granulomatous infections it was 1.23 (95% confidence interval 0.82-1.84). Using methotrexate as comparator and comparing first year of exposure with later exposure did not modify the results. For any infectious episode, risks and relative risks were heterogeneous among registries, probably because of different definitions of outcome. LIMITATIONS There was lack of power to describe risk of single drugs. CONCLUSION In current clinical practice, treatment with anti-TNF drugs was not associated with a higher risk of serious infections than treatment with nonbiologic systemic therapy.

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results